186 related articles for article (PubMed ID: 31559562)
21. Unrelated volunteer bone marrow transplantation: initial experience at St Vincent's Hospital, Sydney.
Atkinson K; Dodds AJ; Concannon AJ; Milliken S; Downs K; Marshall G; Wilson F; Staniforth D
Aust N Z J Med; 1993 Oct; 23(5):450-7. PubMed ID: 8297273
[TBL] [Abstract][Full Text] [Related]
22. A randomized study of cyclosporine and methotrexate with or without methylprednisolone for the prevention of graft-versus-host disease: Improved long-term survival with triple prophylaxis.
Ruutu T; Nihtinen A; Niittyvuopio R; Juvonen E; Volin L
Cancer; 2018 Feb; 124(4):727-733. PubMed ID: 29112242
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic bone marrow transplantation for chronic myeloid leukemia: a single center experience.
Vela-Ojeda J; Tripp-Villanueva F; Sánchez-Cortés E; Ayala-Sánchez M; Rosas-Cabral A; Esparza MG; García-Chávez J; García-León LD; González-Llaven J
Arch Med Res; 2000; 31(2):206-9. PubMed ID: 10880729
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of matched sibling donor bone marrow transplantation in children using single-agent calcineurin inhibitors as prophylaxis for graft versus host disease.
Elgarten CW; Arnold DE; Bunin NJ; Seif AE
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28748621
[TBL] [Abstract][Full Text] [Related]
25. Effect of donor CTLA-4 alleles and haplotypes on graft-versus-host disease occurrence in Tunisian patients receiving a human leukocyte antigen-identical sibling hematopoietic stem cell transplant.
Sellami MH; Bani M; Torjemane L; Kaabi H; Ladeb S; Ben Othmane T; Hmida S
Hum Immunol; 2011 Feb; 72(2):139-43. PubMed ID: 21081144
[TBL] [Abstract][Full Text] [Related]
26. The use of counterflow centrifugal elutriation for the depletion of T cells from unrelated donor bone marrow.
Neudorf SM; Rybka W; Ball E; Blatt J; Bloom E; Corey S; deMagalhaes-Silverman M; Koehler M; Lister J; Mierski J; Mirro J; Pincus S; Wilson J; Wollman M; Donnenberg AD
J Hematother; 1997 Aug; 6(4):351-9. PubMed ID: 9377073
[TBL] [Abstract][Full Text] [Related]
27. Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate.
Kanda Y; Izutsu K; Hirai H; Sakamaki H; Iseki T; Kodera Y; Okamoto S; Mitsui H; Iwato K; Hirabayashi N; Furukawa T; Maruta A; Kasai M; Atsuta Y; Hamajima N; Hiraoka A; Kawa K
Leukemia; 2004 May; 18(5):1013-9. PubMed ID: 15029208
[TBL] [Abstract][Full Text] [Related]
28. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants.
Middleton PG; Taylor PR; Jackson G; Proctor SJ; Dickinson AM
Blood; 1998 Nov; 92(10):3943-8. PubMed ID: 9808588
[TBL] [Abstract][Full Text] [Related]
29. Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis.
Qayed M; Wang T; Hemmer MT; Spellman S; Arora M; Couriel D; Alousi A; Pidala J; Abdel-Azim H; Aljurf M; Ayas M; Bitan M; Cairo M; Choi SW; Dandoy C; Delgado D; Gale RP; Hale G; Frangoul H; Kamble RT; Kharfan-Dabaja M; Lehman L; Levine J; MacMillan M; Marks DI; Nishihori T; Olsson RF; Hematti P; Ringden O; Saad A; Satwani P; Savani BN; Schultz KR; Seo S; Shenoy S; Waller EK; Yu L; Horowitz MM; Horan J
Biol Blood Marrow Transplant; 2018 Mar; 24(3):521-528. PubMed ID: 29155316
[TBL] [Abstract][Full Text] [Related]
30. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
Atkinson K; Downs K
Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis.
Carlens S; Ringdén O; Remberger M; Lönnqvist B; Hägglund H; Klaesson S; Mattsson J; Svahn BM; Winiarski J; Ljungman P; Aschan J
Bone Marrow Transplant; 1998 Oct; 22(8):755-61. PubMed ID: 9827972
[TBL] [Abstract][Full Text] [Related]
32. Influence of one human leukocyte antigen mismatch on outcome of allogeneic bone marrow transplantation from related donors.
Hasegawa W; Lipton JH; Messner HA; Jamal H; Yi QL; Daly AS; Kotchetkova N; Kiss TL
Hematology; 2003 Feb; 8(1):27-33. PubMed ID: 12623424
[TBL] [Abstract][Full Text] [Related]
33. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
34. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
[TBL] [Abstract][Full Text] [Related]
35. Incidence of graft vs host disease in allogeneic bone marrow transplantation in a single center study from Turkey.
Ilhan O; Akan H; Koç H; Gürman G; Arslan O; Ozcan M; Erdi H; Erdem C; Konuk N; Uysal A; Beksaç M
Hematol Cell Ther; 1997 Jun; 39(3):133-6. PubMed ID: 9262989
[TBL] [Abstract][Full Text] [Related]
36. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
[TBL] [Abstract][Full Text] [Related]
37. Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants.
Gaziev D; Galimberti M; Lucarelli G; Polchi P; Giardini C; Angelucci E; Baronciani D; Sodani P; Erer B; Biagi MD; Andreani M; Agostinelli F; Donati M; Nesci S; Talevi N
Bone Marrow Transplant; 2000 Apr; 25(8):815-21. PubMed ID: 10808201
[TBL] [Abstract][Full Text] [Related]
38. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC
Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846
[TBL] [Abstract][Full Text] [Related]
39. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age.
Kollman C; Howe CW; Anasetti C; Antin JH; Davies SM; Filipovich AH; Hegland J; Kamani N; Kernan NA; King R; Ratanatharathorn V; Weisdorf D; Confer DL
Blood; 2001 Oct; 98(7):2043-51. PubMed ID: 11567988
[TBL] [Abstract][Full Text] [Related]
40. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study.
Ruutu T; Volin L; Parkkali T; Juvonen E; Elonen E
Blood; 2000 Oct; 96(7):2391-8. PubMed ID: 11001889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
